Up To Five S. Korean Pharmas Halt Certain Drug Sales In Asbestos Scare
This article was originally published in PharmAsia News
Several South Korean pharmaceutical companies have halted sales of antibiotics and six other drugs following a discovery they might be contaminated with asbestos, a carcinogen. The names of the four or five companies believed taking the precautionary action were not released, but their drugs are said to be suspected of containing talc contaminated with asbestos. Talc often is used in the molding process and for polishing. A primary supplier was Duksan Pure Chemicals. In addition to antibiotics, possibly tainted drugs include antacids and hemostatic powder. (Click here for more)
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.